The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Strategies to improve biomarker testing in the UK
Alastair Greystoke, PhD, MBChB, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, describes the current state of biomarker testing in the UK and approaches to improve testing. Increased testing is required for patients to access suitable treatment, and Genomic Laboratory Hubs (GLHs) have aimed to offer genetic panel testing to patients throughout the UK. Prof. Greystoke additionally highlights how streamlining testing timelines is important for patients to receive treatment in a timely manner. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Prof. Greystoke reports consultancy and speaker fees from AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen/ J and J, MSD, Novartis, Pfizer, Lilly, Takeda and Roche; and research funding from AstraZeneca. He is also the clinical Lead for Cancer North East England Hull and Yorkshire Genomic Laboratory Hub and a member of the National Test Directory Evaluation Working Group.
